While the world obsesses over AI hype, Celegence is building a $41.6M empire solving the unsexy but critical problem of global medical device compliance. In an industry where regulatory missteps can kill products overnight, they've positioned themselves as the invisible backbone for pharma giants.

"Regulatory compliance isn't sexy, but it's where billion-dollar products live or die. Celegence owns the infrastructure."

Their tech stack reveals a pragmatic approach: jQuery, Bootstrap, and Tailwind CSS for rapid development, not bleeding-edge frameworks. This isn't a startup burning cash on flashy frontends—it's a revenue-focused operation building tools that work. The lack of Trustpilot reviews isn't a red flag; it's a signal they're B2B-first, selling to regulated enterprises that don't leave public reviews.

• CEO Sonia Veluchamy leads a team of 207 specialists in medical writing and regulatory affairs
• Top keywords show deep domain expertise: 'regulatory affairs labeling' (1,010 monthly volume) and 'what is dmf' (720 monthly volume)
• Global rank of #1,821,545 suggests they're not optimizing for traffic—just for the right traffic
• The 'undefined' top countries indicate either data limitations or a truly global client base without regional concentration